FDA delays review of AZ's Brilinta
AstraZeneca said today that the FDA has extended the time to complete its review of its application for Brilinta (ticagrelor). The PDUFA date has been moved from September 16 to December 16. Release
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Senior Scientist - Permanent Job
Yoh - Doylestown, PA, USA -
Aseptic Operations Manager
DPT Labs - Lakewood, NJ -
Director, Clinical Safety
Daiichi Sankyo - Edison, NJ -
Supervisor, QC Chemistry - 3rd Shift Job
Celgene Corporation - Phoenix, AZ, US -
Neurosciences Knowledge Group Lead
Merck - Rahway, NJ - Kenilworth, NJ - West Point, PA - Boston, MA
Comments